Pulse Biosciences, Inc (NASDAQ:PLSE) Stock Now Rated "Moderate Buy" by Wall Street Analysts

Key Points

• Pulse Biosciences received a “Moderate Buy” consensus rating from seven analysts, with five buys, one strong buy, and one sell. The average 12-month price target is $60.20, including targets as high as $70.
• Insider buying totaled 4,095 shares worth approximately $199,931 over the past 90 days, while insiders own 74% of the company; institutional investors hold 76.95%.
• Shares opened at $52.24 after a 5.8% decline, despite trading well above their 52-week low of $12.56. The company recently missed quarterly earnings and revenue estimates, reporting a loss of $0.36 per share on $0.43 million in revenue.

Shares of Pulse Biosciences, Inc (NASDAQ:PLSE - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the seven research firms that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $60.20.

PLSE has been the subject of several recent analyst reports. BTIG Research started coverage on Pulse Biosciences in a research note on Wednesday, September 23rd. They set a "buy" rating and a $70.00 price target for the company. Freedom Capital raised Pulse Biosciences to a "strong-buy" rating in a research note on Wednesday, September 9th. Mizuho set a $55.00 price objective on Pulse Biosciences in a research note on Tuesday, October 13th. Canaccord Genuity Group boosted their target price on Pulse Biosciences from $43.00 to $58.00 and gave the stock a "buy" rating in a report on Tuesday, October 6th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Pulse Biosciences in a research report on Thursday, October 15th.

Insider Activity at Pulse Biosciences

In other news, COO Liane Teplitsky purchased 1,036 shares of the company's stock in a transaction dated Wednesday, August 26th. The shares were bought at an average price of $48.23 per share, with a total value of $49,966.28. Following the completion of the transaction, the chief operating officer directly owned 1,036 shares in the company, valued at $49,966.28. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have purchased a total of 4,095 shares of company stock valued at $199,931 over the last 90 days. Company insiders own 74.00% of the company's stock.

Institutional Trading of Pulse Biosciences

Large investors have recently modified their holdings of the company. Sterling Capital Management LLC increased its position in Pulse Biosciences by 844.6% in the third quarter. Sterling Capital Management LLC now owns 614 shares of the company's stock worth $31,000 after purchasing an additional 549 shares during the period. Osterweis Capital Management Inc. acquired a new position in Pulse Biosciences during the 2nd quarter valued at about $28,000. Axxcess Wealth Management LLC acquired a new position in Pulse Biosciences during the 3rd quarter valued at about $242,000. Bender Robert & Associates bought a new position in shares of Pulse Biosciences in the 3rd quarter valued at about $379,000. Finally, Jupiter Topco LLC bought a new position in shares of Pulse Biosciences in the 2nd quarter valued at about $241,000. 76.95% of the stock is owned by institutional investors.

Pulse Biosciences Trading Down 5.8%

PLSE stock opened at $52.24 on Friday. Pulse Biosciences has a 1 year low of $12.56 and a 1 year high of $58.90. The company has a fifty day simple moving average of $51.08 and a 200 day simple moving average of $31.29. The firm has a market cap of $3.70 billion, a PE ratio of -44.27 and a beta of 1.57.

Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.29) by ($0.07). Pulse Biosciences had a negative return on equity of 94.42% and a negative net margin of 6,755.78%. The business had revenue of $0.43 million during the quarter, compared to the consensus estimate of $0.53 million. As a group, analysts forecast that Pulse Biosciences will post -1.34 EPS for the current fiscal year.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc NASDAQ: PLSE is a medical technology company developing bioelectric therapies based on its Nano-Pulse Stimulation (NPS) technology. The technology uses short, high-voltage electrical pulses to create temporary openings in cell membranes, with the goal of selectively affecting targeted cells while limiting thermal damage to surrounding tissue.

The company's principal product is the CellFX System, a device designed to deliver NPS treatments for certain dermatologic conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.